Why the study?
Do non-invasive blood circulating biomarkers accurately assess disease progression and response to therapies in Duchenne muscular dystrophy patients compared to current invasive and complex physical tests?
Population
Duchenne muscular dystrophy (DMD) patients
Comparison
Non-invasive blood circulating biomarkers vs Current assessments including complex physical…
Design
Review
Authors
Loading...
May support less invasive DMD monitoring; leaves open prospective validation before adoption.
Do non-invasive blood circulating biomarkers accurately assess disease progression and response to therapies in Duchenne muscular dystrophy patients compared to current invasive and complex physical tests?
Non-invasive blood circulating biomarkers offer a promising alternative to invasive muscle biopsies and complex physical tests for monitoring disease progression and therapeutic response in Duchenne muscular dystrophy.
Hathout et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: